Scientists have discovered that a protein linked to prostate cancer is associated with more aggressive disease and could be a new target for treatment.

The team at The Institute of Cancer Research, London, UK, have shown that the BCL2 protein was abundant in a subtype of advanced prostate cancer which has stopped responding to hormone therapy.

The researchers estimate that around 10% of people with prostate cancer have high levels of this protein. They have proposed a new treatment strategy to target BCL2 – a protein responsible for preventing cell death.

A clinical trial for prostate cancer testing the BCL2 inhibitor venetoclax – a drug approved for types of leukaemia – with the hormone therapy enzalutamide has already begun.

Professor Kristian Helin, Chief Executive of The Institute of Cancer Research, London, said: “This research has helped to identify a subset of patients who might respond better to alternatives to hormone therapy, and who may benefit even further from a BCL2 inhibitor. I look forward to seeing tests which pick out these patients and am hopeful these findings will lead to new treatment strategies for patients with advanced prostate cancer.”

The impact of BCL2 level on treatment outcome

The researchers examined 427 biopsies from 245 patients with metastatic castration-resistant prostate cancer (mCRPC).

They found that patients with higher levels of BCL2 had a significantly shorter overall survival from the time of diagnosis of mCRPC, of 20.4 months compared with 53.0 months.

They also found a significant difference in response to common hormone therapy treatments, depending on the cancer’s level of BCL2.

The PSA level – a marker of prostate cancer – fell by more than 50% in only 12.5% of those with higher levels of BCL2, compared with 47.6% of patients with lower expression of BCL2.

The overall survival from starting therapy was also markedly different, at 9.7 months for those with higher levels of BCL2 compared with 24.3 months.

However, the researchers found no difference in overall survival or PSA response when cancers were treated with the chemotherapy docetaxel, suggesting this could be a better treatment for patients with high levels of BCL2.

In the lab, the team found the best anti-tumour response in cells when they targeted the BCL2 ‘family’ of proteins together – BCL2, BCLXL and MCL1 – due to the interactions between these proteins in the body.

Professor Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust said: “If targeting BCL2 proves effective in clinical trials, patients with advanced prostate cancer will be able to look forward to better, personalised treatments. Our research has also suggested a combination strategy for therapies which should be explored and may prove even more effective than targeting BCL2 alone.”

Diana Spencer, Senior Digital Content Editor, DDW